CTLT vs. TEVA, BGNE, RDY, QGEN, ROIV, LNTH, RVMD, SMMT, ELAN, and KRYS
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries (NYSE:TEVA) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Teva Pharmaceutical Industries has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Catalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries received 678 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 67.69% of users gave Teva Pharmaceutical Industries an outperform vote while only 58.66% of users gave Catalent an outperform vote.
In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Catalent. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 8 mentions for Catalent. Teva Pharmaceutical Industries' average media sentiment score of 0.89 beat Catalent's score of 0.74 indicating that Catalent is being referred to more favorably in the news media.
Teva Pharmaceutical Industries has a net margin of -2.88% compared to Teva Pharmaceutical Industries' net margin of -26.61%. Catalent's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 0.3% of Catalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Teva Pharmaceutical Industries presently has a consensus target price of $18.56, suggesting a potential upside of 8.48%. Catalent has a consensus target price of $55.65, suggesting a potential downside of 5.16%. Given Catalent's stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Catalent.
Summary
Teva Pharmaceutical Industries beats Catalent on 13 of the 18 factors compared between the two stocks.
Get Catalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
Related Companies and Tools
